Response to the FDA's May 23, 2007, Nephrogenic Systemic Fibrosis Update
- 1 January 2008
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 246 (1) , 11-14
- https://doi.org/10.1148/radiol.2461071267
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?Acta Radiologica, 2007
- Nephrogenic Systemic Fibrosis: Risk Factors and Incidence EstimationRadiology, 2007
- Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Yearbook of Diagnostic Radiology, 2007
- Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a reviewFundamental & Clinical Pharmacology, 2006
- Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamideEuropean Radiology, 2006
- Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 TeslaInvestigative Radiology, 2006